Cardiovascular Risk in Autoimmune Diseases: Mechanisms, Management, and Emerging Evidence

Area of Science:

• Immunology
• Cardiology
• Rheumatology

Background:

• Autoimmune disorders significantly increase cardiovascular disease (CVD) risk, leading to morbidity and mortality.
• Chronic inflammation in conditions like rheumatoid arthritis and lupus accelerates atherosclerosis and vascular complications.
• Dysregulated immune pathways, autoantibodies, and traditional risk factors contribute to endothelial dysfunction and metabolic disturbances.

Purpose of the Study:

• To review the mechanisms linking autoimmune diseases to cardiovascular complications.
• To discuss current and emerging management strategies for cardiovascular risk in autoimmune populations.
• To highlight the role of targeted therapies and lifestyle interventions in improving cardiovascular outcomes.

Main Methods:

• Literature review of cohort studies and clinical trials.
• Analysis of pathophysiologic mechanisms including inflammation, cytokines, and autoantibodies.
• Evaluation of management strategies incorporating cardiovascular prevention and immunomodulatory treatments.

Main Results:

• Persistent inflammation and disease-specific factors accelerate atherosclerosis in autoimmune patients.
• Biologic therapies targeting inflammatory mediators show promise in reducing cardiovascular risk.
• Integrated management of systemic inflammation and cardiovascular risk factors improves patient outcomes.
• Advanced imaging and biomarkers aid in early detection of subclinical atherosclerosis.

Conclusions:

• Cardiovascular health in autoimmune disease requires comprehensive management focusing on systemic inflammation control.
• Targeted immunotherapies, lifestyle modifications, and standard cardiovascular care are essential.
• Ongoing research into immune pathways and risk factors will further refine prevention and treatment strategies.